Please assess the completion status of the following clinical trial:

Trial Title: Platelet Inhibition With Cangrelor and Crushed Ticagrelor in STEMI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Patients with STEMI undergoing primary PPCI~* Age \> 18 years old~Exclusion criteria:~* Inability to provide written informed consent~* Known history of prior intracranial bleeding~* On treatment with a P2Y12 receptor antagonist (ticlopidine, clopidogrel, prasugrel, ticagrelor) in the prior 10 days~* Known allergies to aspirin, ticagrelor or cangrelor~* On treatment with oral anticoagulant~* Treatment with glycoprotein IIb/IIIa inhibitors~* Fibrinolytics within 24 hours~* Active bleeding~* High risk of bleeding~* Known platelet count \<80x106/mL~* Known hemoglobin \<10 g/dL~* Intubated patients (prior to randomization)~* Known creatinine clearance \<30 mL/minute or on hemodialysis.~* Known severe hepatic dysfunction~* Patients with sick sinus syndrome (SSS) or high degree AV block without pacemaker protection~* Current treatment with drugs interfering with CYP3A4 metabolism (to avoid interaction with ticagrelor): Ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir, and telithromizycin.~* Pregnant or lactating females.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cangrelor (Type: EXPERIMENTAL): Cangrelor will be administered as 30 μg/kg bolus followed by 4 μg/kg/min infusion for 2 hours
- Placebo (Type: PLACEBO_COMPARATOR): Normal saline bolus and infusion for 2 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).